The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase I/Ib, open-label, dose-finding study to evaluate safety, pharmacodynamics, and efficacy of pembrolizumab (MK-3475) in combination with vorinostat in patients with advanced renal or urothelial cell carcinoma.
 
Roberto Pili
Research Funding - Merck
 
David Quinn
No Relationships to Disclose
 
Noah M. Hahn
Consulting or Advisory Role - AstraZeneca/MedImmune; Bristol-Myers Squibb; Inovio Pharmaceuticals; Medivation; Merck; Oncogenex; Pieris Pharmaceuticals
Research Funding - Abbott Laboratories (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Genentech/Roche (Inst); Heat Biologics (Inst); Merck (Inst); Merck (Inst); Millennium (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Novartis (Inst); Oncogenex (Inst); Sanofi (Inst)
 
Costantine Albany
Consulting or Advisory Role - Seagen
Speakers' Bureau - Bayer
 
Theodore F. Logan
Consulting or Advisory Role - Prometheus
Research Funding - Merck (Inst)
 
Charles G. Drake
No Relationships to Disclose